| Western Ill Home Hlth Care In | |
| 2 Industrial Park Avenue, Monmouth, Illinois 61462 | |
| (309) 734-9376 | |
| Name | Western Ill Home Hlth Care In |
|---|---|
| Location | 2 Industrial Park Avenue, Monmouth, Illinois |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 147204 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 61201, 61231, 61260, 61265, 61272, 61279, 61401, 61410, 61412, 61413, 61414, 61415, 61416, 61417, 61418, 61422, 61423, 61427, 61428, 61430, 61431, 61434, 61435, 61438, 61440, 61441, 61443, 61447, 61448, 61450, 61452, 61454, 61455, 61459, 61462, 61467, 61469, 61470, 61472, 61473, 61474, 61475, 61480, 61482, 61484, 61485, 61486, 61488, 61489, 61490, 61501, 61519, 61520, 61524, 61531, 61533, 61542, 61572, 62321, 62326, 62354, 62367, 62374, 62644, 62681 |
| NPI Number | 1831203546 |
| Organization Name | WESTERN ILLINOIS HOME HEALTH CARE, INC. |
| Address | 2 Industrial Park Ave, Monmouth, IL 61462 |
| Phone Number | 309-734-9376 |
News Archive
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.
f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H today announced the signing of a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star's Modular Antibody Technology.
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.
› Verified 1 days ago
| Quality Rating: |
News Archive
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.
f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H today announced the signing of a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star's Modular Antibody Technology.
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 97.9 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 96.7 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 80.1 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 89.3 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 96.5 | 96.4 |
News Archive
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.
f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H today announced the signing of a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star's Modular Antibody Technology.
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 82.4 | 79.6 |
| How often patients got better at getting in and out of bed | 88.5 | 81.1 |
| How often patients got better at bathing | 83.8 | 82.3 |
| How often patients’ breathing improved | 82.5 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 79.9 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 77.6 | 75 |
| How often home health patients had to be admitted to the hospital | 16.3 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 18 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 91.5 | 94 |
News Archive
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.
f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H today announced the signing of a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star's Modular Antibody Technology.
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.
› Verified 1 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.
f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H today announced the signing of a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star's Modular Antibody Technology.
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.
› Verified 1 days ago
The patient survey data of Western Ill Home Hlth Care In is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 88 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 82 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 80 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 81 | 78 |
News Archive
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.
f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H today announced the signing of a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star's Modular Antibody Technology.
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.
› Verified 1 days ago
Western Ill Home Hlth Care In Location: 2 Industrial Park Avenue, Monmouth, Illinois 61462 Ratings: Phone: (309) 734-9376 |